atopic dermatitis

Fitting inThe approval of dupilumab (Dupixent, Sanofi Regeneron) for moderate-to-severe atopic dermatitis adds a much-needed option that may alter the broader course of atopic disease, experts told Dermatology Times.
IL-31 at center stageA novel interleukin (IL) antagonist currently in phase 2 studies could advance the treatment of atopic dermatitis (AD), according to dermatologist.
Atopic dermatitis comorbiditiesEmerging data suggest that atopic dermatitis is not just a skin disease. In terms of its impact on the whole patient and its potential for multi-organ involvement, it is a systemic disease, according to one dermatologist.
Top 3 atopic dermatitis articles
Top 3 atopic dermatitis articlesAtopic dermatitis (AD) is one of the most common skin conditions treated by dermatologists. As such, articles on atopic dermatitis tend to be some of the most popular Dermatology Times content. These are the top three AD articles.
Treating eczemas in skin of colorWhen it comes to treating atopic dermatitis in non-white racial ethnic groups, there are variations in prevalence, genetic factors and clinical presentation.
Atopic dermatitis infections that persistAtopic dermatitis normalizes the skin micro biome. Anti-inflammatory medications for atopic dermatitis reduce colonization. Children with atopic dermatitis more prone to molluscum infection.
New treatments on the horizonEmerging therapies are showing impressive efficacy and good tolerability, according to one dermatologist.
Autoimmune drug pipeline: What health execs should watchNew drugs for RA, psoriasis, type 1 diabetes and Crohn’s disease—some recently approved and others coming down the pipeline—could have an impact on the industry.
Study finds significant inpatient burden for AD patientsA recent study looked at the inpatient burden on patients with atopic dermatitis (AD) in the United States and found a significant financial burden due to the high hospitalization rates.
Impact of childhood atopic dermatitisInstructional handouts help caregivers stick to complicated treatment plans for pediatric AD patients. Historically effective AD treatments are being augmented with new phosphodiesterase inhibitors and biologics. Gentler approaches such as massage, light therapy, and melatonin may also be of value for children with AD.